Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5874046 | 0.91 | JAK2 (0.47) | GPR119GRM5JAK2JAK1POLB | |
| SCHEMBL30936178 | 0.89 | GPR119 (0.44) | GPR119GRM5JAK2JAK1POLB | |
| SCHEMBL30017613 | 0.88 | JAK2 (0.50) | GPR119GRM5JAK2JAK1POLB | |
| SCHEMBL760836 | 0.88 | JAK2 (0.50) | GPR119GRM5JAK2JAK1POLB | |
| SCHEMBL25299744 | 0.82 | GPR119 (0.50) | GPR119GRM5JAK2JAK1POLB | |
| SCHEMBL25262300 | 0.81 | GPR119 (0.49) | GPR119GRM5JAK2JAK1POLB | |
| SCHEMBL31327729 | 0.81 | CTSL (0.45) | GPR119POLB | |
| SCHEMBL31417084 | 0.81 | JAK2 (0.45) | GPR119JAK2JAK1POLB | |
| SCHEMBL18340927 | 0.81 | CTSL (0.41) | GPR119JAK2JAK1RORC | |
| SCHEMBL3894380 | 0.80 | PRKCA (0.43) | HSD11B1VNN1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| EP-1745018-A1 | AZETIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005110983-A1 | AZETIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110983-A1 | AZETIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | SLC1A2, SLC18A2, SLC1A1 | GPR119 278/4885GRM5 75/4885JAK2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.